Sandoz Group AG (VIE:SDZ)
Austria · Delayed Price · Currency is EUR | Market Cap | 29.77B +97.0% |
| Revenue (ttm) | 9.50B +7.4% |
| Net Income | 778.45M |
| EPS | 1.78 |
| Shares Out | n/a |
| PE Ratio | 38.25 |
| Forward PE | 19.89 |
| Dividend | 0.86 (1.21%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | n/a |
| Average Volume | 130 |
| Open | 68.74 |
| Previous Close | 68.82 |
| Day's Range | 68.36 - 68.74 |
| 52-Week Range | 52.52 - 78.84 |
| Beta | n/a |
| RSI | 46.08 |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Sandoz Signs Rwanda Deal To Expand Access To Affordable Medicines Across Africa
(RTTNews) - Sandoz AG (SDZNY) announced on Wednesday, that it has signed a direct manufacturing and supply agreement with the Rwanda government to ensure a stable supply of essential medicines, with p...
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG Earnings Call Transcript: Q4 2025
Net sales grew 5% to $11.1B in 2025, with biosimilars now 30% of sales and core EBITDA margin up to 21.7%. Strong launches, strategic acquisitions, and robust pipeline support mid to high single-digit sales growth in 2026, despite ongoing generics pricing pressures.
Sandoz Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted a strong focus on biosimilars and generics, with robust financials, a leading global pipeline, and major investments in manufacturing and innovation. Strategic launches, regulatory tailwinds, and a shift toward biologics position the company for accelerated growth beyond 2028.
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Sandoz Group AG Transcript: Jefferies London Healthcare Conference 2025
The session highlighted a conservative approach to GLP-1 expansion, a strong focus on biosimilars with multiple launches, and strategic acquisitions to enhance control and flexibility. Financial guidance remains on track, with operational efficiency and pipeline growth prioritized.
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
Sandoz Group AG Earnings Call Transcript: Q3 2025
Delivered 5% net sales growth and upgraded core EBITDA margin guidance to 21%-22%, driven by strong biosimilar launches and commercial execution. Biosimilars now represent a record 31% of net sales, with further launches and pipeline expansion supporting sustained growth.
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
PRINCETON, N.J.--(BUSINESS WIRE)--Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent appro...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support gl...
Sandoz Group AG Earnings Call Transcript: Q2 2025
Delivered strong H1 2025 results with 6% underlying sales growth, 2.5pp EBITDA margin expansion, and biosimilars reaching 30% of Q2 net sales. Confirmed full-year guidance, expanded manufacturing, and announced a $300M biosimilar acquisition.
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, t...
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard ...
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
Sandoz Group AG Transcript: Life Sciences Virtual Investor Forum
Strong growth in biosimilars and a robust pipeline are driving double-digit sales increases, with a focus on expanding access to affordable medicines globally. Financial performance is solid, with margin expansion, increased dividends, and a strong balance sheet supporting midterm growth targets.
Sandoz Group AG Transcript: Jefferies Global Healthcare Conference 2025
Sales surpassed $10 billion with strong biosimilar growth and a strategic shift toward biosimilars. Margin and dividend improvements are on track, with regulatory changes potentially lowering development costs. Regional strength in Europe and new launches, including GLP-1 and denosumab, support midterm growth targets.
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...